Literature DB >> 12499639

Modulation of multidrug resistance by artemisinin, artesunate and dihydroartemisinin in K562/adr and GLC4/adr resistant cell lines.

Paiboon Reungpatthanaphong1, Samlee Mankhetkorn.   

Abstract

Overcoming MDR (multidrug resistance) phenomena is a crucial aspect of cancer chemotherapy research. Artemisinin and its derivatives have been found to inhibit the proliferation of cancer cells in the microM range. They poorly inhibited the function of P-glycoprotein and did not inhibit the function of MRP1-protein. The concentrations required to inhibit by 50% the function of P-glycoprotein are 110+/-5 microM. Artemisinin, artesunate and dihydroartemisinin efficiently decreased the mitochondrial membrane potential, leading to a decrease in intracellular ATP in all cell lines tested: by 30 to 50% at 5 microM. Artemisinin, artesunate and dihydroartemisinin increased cytotoxicity of pirarubicin and doxorubicin in P-glycoprotein-overexpressing K562/adr, and in MRP1-overexpressing GLC4/adr, with the delta(0.5) ranging from 200 to 860 nM, but not in their corresponding drug-sensitive cell lines. In this range of concentrations these compounds did not decrease the function of P-glycoprotein, suggesting a mechanism by which the drugs did not reverse MDR phenomenon at the P-glycoprotein level but at the mitochondrial level.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12499639     DOI: 10.1248/bpb.25.1555

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  19 in total

1.  Characterization of dihydroartemisinin-resistant colon carcinoma HCT116/R cell line.

Authors:  Jin-Jian Lu; Si-Meng Chen; Jian Ding; Ling-Hua Meng
Journal:  Mol Cell Biochem       Date:  2011-09-30       Impact factor: 3.396

2.  Computational models to assign biopharmaceutics drug disposition classification from molecular structure.

Authors:  Akash Khandelwal; Praveen M Bahadduri; Cheng Chang; James E Polli; Peter W Swaan; Sean Ekins
Journal:  Pharm Res       Date:  2007-09-11       Impact factor: 4.200

Review 3.  Development of artemisinin compounds for cancer treatment.

Authors:  Henry C Lai; Narendra P Singh; Tomikazu Sasaki
Journal:  Invest New Drugs       Date:  2012-08-31       Impact factor: 3.850

4.  Potential P-glycoprotein-mediated drug-drug interactions of antimalarial agents in Caco-2 cells.

Authors:  Enoche F Oga; Shuichi Sekine; Yoshihisa Shitara; Toshiharu Horie
Journal:  Am J Trop Med Hyg       Date:  2012-07       Impact factor: 2.345

Review 5.  Progress of research in antitumor mechanisms with Chinese medicine.

Authors:  Shu-yan Han; Ping-ping Li
Journal:  Chin J Integr Med       Date:  2009-08-18       Impact factor: 1.978

Review 6.  Compounds from Chinese herbal medicines as reversal agents for P-glycoprotein-mediated multidrug resistance in tumours.

Authors:  C Li; B-Q Sun; X-D Gai
Journal:  Clin Transl Oncol       Date:  2014-03-19       Impact factor: 3.405

Review 7.  Antitumor activity of artemisinin and its derivatives: from a well-known antimalarial agent to a potential anticancer drug.

Authors:  Maria P Crespo-Ortiz; Ming Q Wei
Journal:  J Biomed Biotechnol       Date:  2011-11-22

8.  Yeast model uncovers dual roles of mitochondria in action of artemisinin.

Authors:  Wei Li; Weike Mo; Dan Shen; Libo Sun; Juan Wang; Shan Lu; Jane M Gitschier; Bing Zhou
Journal:  PLoS Genet       Date:  2005-09       Impact factor: 5.917

Review 9.  Anticancer Effect of AntiMalarial Artemisinin Compounds.

Authors:  A K Das
Journal:  Ann Med Health Sci Res       Date:  2015 Mar-Apr

10.  Heme mediates cytotoxicity from artemisinin and serves as a general anti-proliferation target.

Authors:  Shiming Zhang; Glenn S Gerhard
Journal:  PLoS One       Date:  2009-10-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.